Tempest Therapeutics, Inc. beat EPS estimates 33% of the time across 3 reported quarters (1 beats, 2 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q22026 FY2026 | $-0.30 | $-0.34 | -13.3% | Miss |
| Q12026 FY2026 | $-0.28 | $-0.51 | -82.1% | Miss |
| Q42025 FY2025 | $-0.62 | $-0.62 | +0.0% | Beat |
Back to TPST overview · TPST holders · TPST KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.